GlobeNewswire

Aurora Signs Collaboration Agreement with Major Research Institute

Dela

Aurora Solar Technologies Inc. / Aurora Signs Collaboration Agreement with Major Research Institute . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

NORTH VANCOUVER, B.C., March 29, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora") ("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82) is pleased to announce that it has entered into a Collaborative Research Agreement (CRA) with the Solar Energy Research Institute of Singapore (SERIS). SERIS is a top-tier applied research institute and has close ties with solar product manufacturers throughout Asia. The purpose of Aurora's joint research with SERIS is to advance the infrared reflection and transmission measurement techniques commercially pioneered in the DecimaTM family of products. The Company expects that this will lead to several new commercial applications for the Decima products in solar cell production and will also create opportunities in the growing R&D market for solar cell design and qualification. Under a separate purchase agreement, Aurora will supply SERIS with its latest Decima infrared measurement system, which will be used to characterize the advanced solar cells developed by SERIS. 

In January, the Company announced a cooperative project with SERIS on extending the Decima measurement capabilities to include heterojunction (HJ) solar cell manufacturing. HJ technology is a high-efficiency solar cell design that is rapidly being adopted in the industry.  This project is already bearing fruit with several solar cell manufacturers expressing interest in evaluating Aurora's HJ capabilities.  Now, with the signing of this CRA, Aurora is joining major cell manufacturers and production equipment makers who are working with SERIS to define and realize the next generation of solar cells, modules and manufacturing technologies as the industry continues growing at over 30 percent per year.

The CRA research is focused on a number of solar cell properties that are critical to quality and performance, such as emitter surface concentration and junction depth that cannot practically be measured in production. Even laboratory testing of these properties is time-consuming and expensive, and in some cases there is no practical way to directly measure the properties at all. However, both Aurora and SERIS anticipate that investigation and further refinement of IR characterization technology can lead to the means to rapidly and easily measure these properties in both volume production and laboratory applications. Realization of these capabilities can have the potential to allow solar cell manufacturers to more quickly and effectively qualify new cell designs, ramp up production lines and control variations in production.

"We have established a strong industry presence with a superior product and increasing orders. This important collaboration will now build on this by combining SERIS' research resources and broad industry contacts with our Decima IR technology base and commercial capabilities. This will enable us to expand our technology capabilities and customer base to meet the continuous demands for more efficient cell designs and process improvements in this explosive global industry," said Gordon Deans, Aurora's Chief Operating Officer.

"We are pleased to be increasing the depth and breadth of our relationship with Aurora," said Dr. Armin Aberle, SERIS' CEO. "In our work to advance the state of the art in the solar energy industry, SERIS works closely with numerous manufacturers and production equipment vendors. We expect that our work with Aurora will make a strong contribution to this industry development."

About Aurora Solar Technologies:

Aurora's mission is to deliver exceptional results to the photovoltaic industry through measurement, visualization and control of critical processes during solar cell manufacturing. We measure and map the results of critical cell fabrication processes, providing real-time visualization of material properties, cell parameters and production tool performance. Our products provide process engineers and production-line operators with the means to rapidly detect, analyze and correct process excursions, limit variations, and optimize processes, thereby increasing yield and profits. We are creating the quality control standard for the global photovoltaic manufacturing industry.  For more information, Aurora's website is located at www.aurorasolartech.com.

About the Solar Energy Research Institute of Singapore (SERIS):

The Solar Energy Research Institute of Singapore (SERIS) at the National University of Singapore (NUS) is Singapore's national institute for applied solar energy research. SERIS conducts research, development, testing and consulting on solar energy technologies and their integration into power systems and buildings. The Institute's R&D spectrum covers materials, components, processes, systems and services, with an emphasis on solar photovoltaic cells, modules and systems. SERIS' research team includes more than 200 scientists, engineers, technicians and Ph.D. students. SERIS collaborates closely with universities, research organizations, government agencies and industry. The collaborations with companies from the global solar sector span from small start-ups to industry leading heavyweights. For more information, SERIS' website is located at www.seris.sg.

For further information contact:

Michael Heaven, P.Eng., MBA
President & Chief Executive Officer
Aurora Solar Technologies Inc. 
Phone: +1 (778) 241-5000 
info@aurorasolartech.com

Investor Relations contact:
Nina Lafleur
Phone: +1 (604) 679-9964
info@aurorasolartech.com

Paradox Public Relations
Phone: +1 (514) 341-0408
info@paradox-pr.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward­ looking information. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. The Company does not assume the obligation to update any forward­ looking statement.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aurora Solar Technologies Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum